CSNK2A1 and pancreatic ductal adenocarcinoma: Silmitasertib, a specific inhibitor of CSNK2A1, has been shown to restore gemcitabine sensitivity in pancreatic ductal adenocarcinoma, a cancer notoriously resistant to chemotherapy [37].